RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
RETA
Delisted
RETA was delisted on the 25th of September, 2023.
201 hedge funds and large institutions have $2.52B invested in Reata Pharmaceuticals, Inc. Class A Common Stock in 2021 Q1 according to their latest regulatory filings, with 38 funds opening new positions, 78 increasing their positions, 55 reducing their positions, and 38 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
less funds holding
Funds holding: →
less capital invested
Capital invested by funds: $ → $
34% less call options, than puts
Call options by funds: $28.7M | Put options by funds: $43.8M
56% less funds holding in top 10
Funds holding in top 10: 9 → 4 (-5)
Holders
201
Holding in Top 10
4
Calls
$28.7M
Puts
$43.8M
Top Buyers
| 1 | +$39.9M | |
| 2 | +$27.6M | |
| 3 | +$27.2M | |
| 4 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
+$26.1M |
| 5 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
+$25.1M |
Top Sellers
| 1 | -$64.9M | |
| 2 | -$42.3M | |
| 3 | -$15.5M | |
| 4 |
AAMU
Amundi Asset Management US
Boston,
Massachusetts
|
-$14.6M |
| 5 |
CCM
CAAS Capital Management
New York
|
-$11.8M |